GGrantIndex
← Leaderboards

Richard C Ahrens

University Of Iowa

$204,951
Attributed
$204,951
Total exposure
24
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $61.5K · FY200507
$100K$75K$50K$25K$0
'05
'06
'07

Funding mix

By agency

NIH$204,951 · 24

By mechanism

M01$204,951 · 24

Top collaborators

No co-investigators on record.

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Cystic Fibrosis

Research focus

Cystic FibrosisClinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationSourceRespiratory Disorder ChemotherapyComputer Retrieval Of Information On Scientific Projects DatabaseResourcesResearch PersonnelInstitutionUnited States National Institutes Of HealthGrantFundingInhalation Drug AdministrationDosageSafetyCystic Fibrosis PatientsRandomizedPlacebosDouble-Blind MethodClinical Trial Phase ILungOral Administration

Grant awards (31)

ULTRASE MT20 FOR CORRECTION OF STEATORRHEA IN PATIENTS WITH CYSTIC FIBROSIS$22,117
M01 · FY2007 · RR · contact PI
ERUAND PANCREATIC ENZYME PRODUCT (PEP) IN PATIENTS WITH CYSTIC FIBROSIS$11,534
M01 · FY2007 · RR · contact PI
EURAND PANCREATIC ENZYME PRODUCT MICROTABS IN PEDIATRIC CF PATIENTS$1,901
M01 · FY2007 · RR · contact PI
GENETIC MODIFIERS OF CYSTIC FIBROSIS: SIBLING STUDY$1,358
M01 · FY2007 · RR · contact PI
ANTIMICROBIAL THERAPY FOR NEW ONSET PSEUDOMONAS AERUGINOSA AIRWAY INFECTION$950
M01 · FY2007 · RR · contact PI
STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS$813
M01 · FY2007 · RR · contact PI
AZTREONAM LYSINATE IN CF PATIENTS WITH PULMONARY PNEUMONIA AERUGINOSA$680
M01 · FY2007 · RR · contact PI
TIOTROPIUM BROMIDE ADMINISTERED VIA THE RESPIMAT DEVICE IN CF PATIENTS$544
M01 · FY2007 · RR · contact PI
MULTICENTER INVESTIGATION OF GENETIC MODIFIER IN CF LUNG OR LIVER DISEASE STUDY$135
M01 · FY2007 · RR · contact PI
INDUCED SPUTUM TO EVALUATE ANTI-INFLAMMATORY AGENTS IN CF PATIENTS$13,897
M01 · FY2006 · RR · contact PI
STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS$4,963
M01 · FY2006 · RR · contact PI
ANTIMICROBIAL THERAPY FOR NEW ONSET PSEUDOMONAS AERUGINOSA AIRWAY INFECTION$2,978
M01 · FY2006 · RR · contact PI
MULTICENTER INVESTIGATION OF GENETIC MODIFIER IN CF LUNG OR LIVER DISEASE STUDY$1,655
M01 · FY2006 · RR · contact PI
ORAL THERACLEC-TOTAL IN CYSTIC FIBROSIS SUBJECTS$55,037
M01 · FY2005 · RR
STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS$3,562
M01 · FY2005 · RR
MULTICENTER INVESTIGATION OF GENETIC MODIFIER IN CF LUNG OR LIVER DISEASE STUDY$1,942
M01 · FY2005 · RR
BIIL 284 BS IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$971
M01 · FY2005 · RR
Oral TheraCLEC to Treat Cystic Fibrosis$7,758
M01 · FY2004 · RR
Aztreonam for Inhalation in Subjects w/ Cystic Fibrosis$4,385
M01 · FY2004 · RR
BIIL 284 BS in Adult and Pediatric Cystic Fibrosis$1,687
M01 · FY2004 · RR
TRIAL OF IB-367 IN ADULT PATIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2002 · RR
ORAL MULTIDOSE CPX IN ADULT PATIENTS W/ CYSTIC FIBROSIS$0
M01 · FY2002 · RR
ELASTASE IN BAL FLUID W TG-HAAT TREATED CYSTIC FIBROSIS$0
M01 · FY2002 · RR
TRIAL OF IB-367 IN ADULT PATIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
ORAL MULTIDOSE CPX IN ADULT PATIENTS W/ CYSTIC FIBROSIS$0
M01 · FY2001 · RR
ELASTASE IN BAL FLUID W TG-HAAT TREATED CYSTIC FIBROSIS$0
M01 · FY2001 · RR
PHASE I TRIAL OF CPX IN ADULTS WITH MILD CYSTIC FIBROSIS$22,028
M01 · FY2000 · RR
ORAL MULTIDOSE CPX IN ADULT PATIENTS W/ CYSTIC FIBROSIS$22,028
M01 · FY2000 · RR
ALBUTEROL BY DRY POWDER INHALER &PRESSURIZED METERED DOSE VENTOLIN INHALER$22,028
M01 · FY2000 · RR
TRIAL OF IB-367 IN ADULT PATIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2000 · RR
ELASTASE IN BAL FLUID W TG-HAAT TREATED CYSTIC FIBROSIS$0
M01 · FY2000 · RR